{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Grade III GVHD represents moderate severity. Grade IV GVHD represents extreme severity","groups":[{"description":"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.\n\nTRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.\n\nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35.","id":"OG000","title":"Treatment (Nonmyeloablative HSCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At any time within 200 days after transplantation","title":"Incidence of Grades III-IV Acute GVHD","type":"PRIMARY","unitOfMeasure":"Participants"}